Neuroectodermal Tumors: Clinical Trials

21 trials for Neuroectodermal Tumors, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

21 suspended. 21 Phase 1, 7 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 121Suspended 21
Phase 27Suspended 7

Follow Neuroectodermal Tumors: new trials by email Literature Review of Neuroectodermal Tumors trials Research Report on Neuroectodermal Tumors

Trials (filtered) newest first · largest first

All 21 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery to Improve Treatment of Melanoma Brain Metastases
Emavusertib, Pembrolizumab, Stereotactic Radiosurgery - Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma
Phase 1 / Phase 2SuspendedMayo Clinic232026-11-302026-10-20
PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma
PEP-CMV vaccine, Tetanus booster, Nivolumab - Diffuse Midline Glioma, Diffuse Midline High-grade Glioma
Phase 1 / Phase 2SuspendedWashington University School of Medicine682026-11-302026-10-30
Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma/Diffuse Midline Glioma and Response to Treatment (Regardless of Mutation Status)
S-Gboxin - Glioblastoma Multiforme, Diffuse Midline Glioma, H3 K27M-Mutant
Phase 1SuspendedPetrov, Andrey102026-05-202026-06-03
Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization
Autologous total tumor mRNA loaded DOTAP liposome vaccine - Melanoma, Soft Tissue Sarcoma
Phase 1SuspendedUniversity of Florida182026-03-172026-09-17
Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
NaviFUS System, Lumason, Bevacizumab - Glioblastoma Multiforme, Glioblastoma
Phase 1 / Phase 2SuspendedNaviFUS Corporation102024-10-222026-09-09
IL13Rα2 CAR-T for Patients With r/r Glioma
IL13Rα2 CAR-T - Glioma
Phase 1SuspendedYang Zhang302024-03-212026-10-01
Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, GD2-CAR PERSIST Trial
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Childhood Neuroblastoma, Recurrent Childhood Osteosarcoma
Phase 1SuspendedNational Cancer Institute (NCI)732022-01-252026-11-18
DNX-2440 for Resectable Colorectal Liver Metastasis
DNX-2440 - Liver Metastases, Liver Metastasis Colon Cancer
Phase 1SuspendedDNAtrix, Inc.302021-02-152024-04-09
Tumor Hypoxia and Proliferation in Patients With High-Grade Glioma
18F-FMISO PET, 18F-FLT PET - Glioma
Phase 1SuspendedWeill Medical College of Cornell University82021-02-012026-01-27
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations
JSI-1187, Dabrafenib - Solid Tumors
Phase 1SuspendedJS InnoPharm, LLC712020-06-182025-09-03
Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM)
Laparoscopically harvested omental free flap - Glioma, Glioma, Malignant
Phase 1SuspendedNorthwell Health102020-01-062026-06-01
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
NeoTCR-P1 adoptive cell therapy, nivolumab, IL-2 - Solid Tumor
Phase 1SuspendedPACT Pharma, Inc.212019-07-032022-08-18
MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b)
FCN-159 - Melanoma
Phase 1SuspendedShanghai Fosun Pharmaceutical Industrial Development Co. Ltd.792019-03-212024-03-27
Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery
Laboratory Biomarker Analysis, Pembrolizumab, Propranolol Hydrochloride - Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Phase 1 / Phase 2SuspendedRoswell Park Cancer Institute472018-01-312026-07-15
Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
P1446A-05, Vemurafenib (Zelboraf®) - Advanced or Inoperable Malignant Melanoma With BRAF Mutation
Phase 1SuspendedPiramal Enterprises Limited1002013-08-012014-09-04
Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma
TPI 287, Bevacizumab - Glioblastoma Multiforme
Phase 1 / Phase 2SuspendedCortice Biosciences, Inc.922013-08-012023-02-22
Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma
Bevacizumab and Carboplatin - Glioblastoma Multiforme, Anaplastic Astrocytoma
Phase 1 / Phase 2SuspendedNorthwell Health542011-09-012026-06-01
Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma
Bevacizumab (Avastin) - Vestibular Schwannoma
Phase 1SuspendedNorthwell Health302011-08-012026-06-01
Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer
Autologous Natural Killer / Natural Killer T Cell Immunotherapy - Breast Cancer, Glioma
Phase 1SuspendedEnvita Medical Center, Inc.242009-05-012010-02-24
Adoptive Cell Transfer Combined With Peptide Vaccination in Transiently Immunosuppressed Melanoma Patients
Melan-A analog peptide - Melanoma
Phase 1SuspendedUniversity of Lausanne Hospitals62004-07-012005-09-12

Showing 20 of 21. Sign in to see all of them.

Narrower conditions

Melanoma (10)  ·  Glioblastoma (5)  ·  Glioma (5)  ·  Brain Neoplasms (4)  ·  Neoplasms (4)  ·  Breast Neoplasms (2)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Carcinoma, Renal Cell (2)  ·  Colorectal Neoplasms (2)  ·  Prostatic Neoplasms (2)  ·  Sarcoma (2)  ·  Astrocytoma (1)  ·  Carcinoma, Squamous Cell (1)  ·  Carcinoma, Transitional Cell (1)  ·  Colonic Neoplasms (1)

Broader conditions

Neoplasms by Histologic Type (21)  ·  Neoplasms, Germ Cell and Embryonal (21)  ·  Neoplasms, Nerve Tissue (20)  ·  Neoplasms (17)  ·  Neoplasms by Site (15)  ·  Neoplasms, Glandular and Epithelial (14)  ·  Neuroendocrine Tumors (11)  ·  Skin Diseases (11)  ·  Skin and Connective Tissue Diseases (11)  ·  Neoplasms, Neuroepithelial (10)  ·  Nevi and Melanomas (10)  ·  Skin Neoplasms (10)  ·  Brain Diseases (5)  ·  Central Nervous System Diseases (5)

Interventions

Bevacizumab (4)  ·  Biopsy (2)  ·  Nivolumab (2)  ·  Specimen Handling (2)  ·  pembrolizumab (2)  ·  CA-4948 (1)  ·  Carboplatin (1)  ·  Cyclophosphamide (1)  ·  Immunoglobulin G (1)  ·  Interleukin-2 (1)  ·  Magnetic Resonance Spectroscopy (1)  ·  Nanoparticles (1)  ·  Propranolol (1)  ·  Radiosurgery (1)  ·  TPI-287 (1)

Sponsors

Northwell Health (3)  ·  Cortice Biosciences, Inc. (1)  ·  DNAtrix, Inc. (1)  ·  Envita Medical Center, Inc. (1)  ·  JS InnoPharm, LLC (1)  ·  Mayo Clinic (1)  ·  MetaPhore Pharmaceuticals (1)  ·  National Cancer Institute (NCI) (1)  ·  NaviFUS Corporation (1)  ·  PACT Pharma, Inc. (1)  ·  Petrov, Andrey (1)  ·  Piramal Enterprises Limited (1)  ·  Roswell Park Cancer Institute (1)  ·  Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (1)  ·  University of Florida (1)

Countries

United States (17)  ·  China (2)  ·  Georgia (1)  ·  Kazakhstan (1)  ·  Switzerland (1)  ·  Ukraine (1)

Top investigators

John Boockvar, MD (3)  ·  Adil Daud, MD (1)  ·  Bently Doonan, MD, MS (1)  ·  David Korn, D.O., M.D. (1)  ·  Eric M Thompson, M.D. (1)  ·  J. P. Duic, M.D. (1)  ·  Jian Campian, M.D. (1)  ·  Joan Robbins, Ph.d (1)  ·  Kevin B Kim, MD (1)  ·  Leighton Elliott, MD (1)  ·  Louis B. Nabors, III, M.D. (1)  ·  Nan Ji, MD, PhD (1)  ·  Nimish Mohile, M.D. (1)  ·  Pierre Giglio, M.D. (1)  ·  Rosandra N Kaplan (1)

Results publications

PMID 35537408, PMID 36113242, PMID 36356599

NIH funding

R01CA296813 (1), U24CA224309 (1), UM1CA154967 (1), UM1CA228823 (1)